

Sonata Jodele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3253381/publications.pdf>

Version: 2024-02-01

72
papers

3,278
citations

147801

31
h-index

155660

55
g-index

73
all docs

73
docs citations

73
times ranked

3055
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. <i>Blood</i> , 2014, 124, 645-653.	1.4	318
2	Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. <i>Blood</i> , 2011, 118, 1452-1462.	1.4	289
3	A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. <i>Blood Reviews</i> , 2015, 29, 191-204.	5.7	270
4	Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. <i>Blood</i> , 2013, 122, 2003-2007.	1.4	237
5	Ecuzumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 518-525.	2.0	218
6	Variable Ecuzumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 307-315.	2.0	125
7	Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with ecuzumab. <i>Blood</i> , 2020, 135, 1049-1057.	1.4	103
8	Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1122-1127.	2.0	96
9	New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. <i>Transfusion and Apheresis Science</i> , 2016, 54, 181-190.	1.0	94
10	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e414-e423.	4.6	92
11	Pulmonary Arterial Hypertension in Pediatric Patients with Hematopoietic Stem Cell Transplantation-associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 202-207.	2.0	79
12	Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. <i>Blood</i> , 2016, 127, 503-512.	1.4	69
13	Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1460-1470.	2.0	65
14	Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1994-2001.	2.0	63
15	Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?. <i>Transfusion</i> , 2013, 53, 661-667.	1.6	59
16	Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1627-1631.	2.0	59
17	Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1671-1677.	2.0	58
18	Abnormal Echocardiography 7 Days after Stem Cell Transplantation May Be an Early Indicator of Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 113-118.	2.0	52

#	ARTICLE	IF	CITATIONS
19	Bortezomib for Refractory Autoimmunity in Pediatrics. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1654-1659.	2.0	47
20	Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies. <i>Seminars in Hematology</i> , 2018, 55, 159-166.	3.4	47
21	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
22	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. <i>Blood Advances</i> , 2021, 5, 1-11.	5.2	46
23	Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1337-1340.	2.0	42
24	High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1311-1318.	2.4	41
25	Interferon-complement loop in transplant-associated thrombotic microangiopathy. <i>Blood Advances</i> , 2020, 4, 1166-1177.	5.2	41
26	Tackling COVID-19 infection through complement-targeted immunotherapy. <i>British Journal of Pharmacology</i> , 2021, 178, 2832-2848.	5.4	39
27	The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3044-3054.	5.8	38
28	Clinical Utility of Computed Tomography and Magnetic Resonance Imaging for Diagnosis of Posterior Reversible Encephalopathy Syndrome after Stem Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2028-2032.	2.0	36
29	Rapid cycle development of a multifactorial intervention achieved sustained reductions in central line-associated bloodstream infections in haematology oncology units at a children's hospital: a time series analysis. <i>BMJ Quality and Safety</i> , 2016, 25, 633-643.	3.7	35
30	Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. <i>Journal of Clinical Immunology</i> , 2020, 40, 699-707.	3.8	35
31	Estimated versus Measured Glomerular Filtration Rate in Children before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2056-2061.	2.0	34
32	A Complete Histologic Approach to Gastrointestinal Biopsy From Hematopoietic Stem Cell Transplant Patients With Evidence of Transplant-Associated Gastrointestinal Thrombotic Microangiopathy. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1558-1566.	2.5	31
33	Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation Patients Despite Both Standard and Aggressive Supplementation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1271-1274.	2.0	27
34	Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. <i>Blood Advances</i> , 2021, 5, 3309-3321.	5.2	26
35	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1273-1277.	2.0	24
36	Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients. <i>Transfusion</i> , 2016, 56, 1402-1405.	1.6	23

#	ARTICLE	IF	CITATIONS
37	In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. <i>Blood Advances</i> , 2017, 1, 1632-1634.	5.2	20
38	Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. <i>Blood Advances</i> , 2020, 4, 5745-5754.	5.2	19
39	A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2220-2225.	2.0	18
40	Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2020, 4, 2158-2162.	5.2	15
41	Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. <i>Experimental Hematology and Oncology</i> , 2021, 10, 57.	5.0	14
42	Increasing Activities of Daily Living Is as Easy as 1-2-3. <i>Journal of Pediatric Oncology Nursing</i> , 2016, 33, 345-352.	1.5	13
43	Team-based approach to identify cardiac toxicity in critically ill hematopoietic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26513.	1.5	13
44	Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. <i>Expert Review of Hematology</i> , 2021, 14, 751-763.	2.2	13
45	Acute Kidney Injury in Children after Hematopoietic Cell Transplantation Is Associated with Elevated Urine CXCL10 and CXCL9. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1266-1272.	2.0	11
46	Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 116.e1-116.e7.	1.2	11
47	Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 392.e1-392.e9.	1.2	11
48	Antibodies to BK virus in children prior to allogeneic hematopoietic cell transplant. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1670-1673.	1.5	9
49	Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 91-95.	2.0	9
50	Association between Vitamin D and Risk for Early and Late Post-Transplant Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 343-350.	2.0	9
51	Endothelial injury, F-actin and vitamin-D binding protein after hematopoietic stem cell transplant and association with clinical outcomes. <i>Haematologica</i> , 2021, 106, 1321-1329.	3.5	8
52	Double trouble: Complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26566.	1.5	7
53	Interleukin-22 levels are increased in gastrointestinal graft-versus-host disease in children. <i>Haematologica</i> , 2018, 103, e480-e482.	3.5	7
54	Haptoglobin degradation product as a novel serum biomarker for hematopoietic stem cell transplant-associated thrombotic microangiopathy. <i>Pediatric Nephrology</i> , 2019, 34, 865-871.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Rapid rituximab infusion is safe in paediatric and young adult patients with non-malignant indications. <i>British Journal of Haematology</i> , 2016, 173, 480-481.	2.5	6
56	Ultra-High Dose Vitamin D in Pediatric Hematopoietic Stem Cell Transplantation: A Nonrandomized Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1001.e1-1001.e9.	1.2	6
57	Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, Publish Ahead of Print, .	0.6	6
58	Topical vitamin D analog for chronic graft versus host disease of the skin. <i>Bone Marrow Transplantation</i> , 2018, 53, 628-633.	2.4	5
59	Multiple bloodstream infections in pediatric stem cell transplant recipients: A case series. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27388.	1.5	5
60	Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure. <i>Blood Advances</i> , 2021, 5, 4594-4604.	5.2	5
61	Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient. <i>Bone Marrow Transplantation</i> , 2018, 53, 487-489.	2.4	3
62	Pneumatosis intestinalis after hematopoietic stem cell transplantation: When not doing anything is good enough. <i>Journal of Pediatric Surgery</i> , 2021, 56, 2073-2077.	1.6	3
63	Testicular thrombotic microangiopathy: An unrecognized complication. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29128.	1.5	3
64	Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29319.	1.5	3
65	The Genetic Fingerprint of Susceptibility to Transplant Associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S98.	2.0	2
66	BK Polyomavirus Genotypes in Two Patients after Hematopoietic Cell Transplant. <i>Microbiology Resource Announcements</i> , 2021, 10, .	0.6	2
67	Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1441-1444.	2.4	2
68	Optimized amplification of BK polyomavirus in urine. <i>Journal of Virological Methods</i> , 2022, 299, 114319.	2.1	2
69	Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 150-156.	2.0	1
70	Kidney Disease in Cancer Survivors: Focus on Hematopoietic Stem Cell Transplantation. <i>Journal of Onco-Nephrology</i> , 2017, 1, 163-169.	0.6	1
71	Abnormal Maximal and Submaximal Cardiopulmonary Exercise Capacity in Pediatric Stem Cell Transplant Recipients Despite Normal Standard Echocardiographic Parameters: A Pilot Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 263.e1-263.e5.	1.2	1
72	BK Polyomavirus Subtypes II and IV in Hematopoietic Cell Transplant Recipients. <i>Microbiology Resource Announcements</i> , 2022, 11, e0105321.	0.6	0